No respite yet on German retrospective re-pricing of Novartis’ gliptins (or other drugs)
This article was originally published in Scrip
Executive Summary
A Berlin court has decided that Novartis must submit its dossier for an AMNOG reimbursement review of Galvus (vildagliptin) by 31 March, even thought the same court is still deciding whether Novartis should have to face the reimbursement review at all. The Swiss company had challenged the review on the basis that the process for retrospective comparisons was not clear.